Compound-diagnostic marker for kidney cancer, method for detecting enzymatic activity, method for diagnosing kidney cancer, kit comprising compound, use of compound, and method for treating kidney cancer
By developing the compound X11-Leu2-Pro3-Gly4-Thr5-X26, using enzymatic cleavage to generate measurable light signals, solving the specificity and sensitivity of early diagnosis of renal cancer, realizing non-invasive detection, significantly improving diagnosis 的准确性和患者生存率。
Patent Information
- Application Number
- CN202380035326.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-20
- Filing Date
- 2023-04-19
- Publication Date
- 2024-12-03
AI Technical Summary
There is a lack of methods and compounds suitable for the specific diagnosis of early renal cancer in the prior art, which makes it difficult to diagnose renal cancer and is not sensitive and specific enough.
A compound X11-Leu2-Pro3-Gly4-Thr5-X26, which contains fluorescent donors and fluorescent acceptor molecules C1 and C2, is developed to generate a measurable light signal through enzymatic cleavage, for detection of kidney cancer-specific enzyme activity. , especially in vitro detection of enzyme activity in subjects' body fluids.
A non-invasive, rapid, sensitive and specific early detection of renal cancer is achieved, suitable for screening tests, and significantly prolongs patient survival time in early diagnosis.
Smart Images

Figure CN119072484A_ABST
Abstract
Description
[0001] The present invention relates to a new compound, a diagnostic marker, for use in the medical field, more specifically for cancer diagnosis, especially for the diagnosis of renal cancer. The present invention also relates to a method for in vitro detection of enzyme activity (especially enzyme activity derived from renal cancer cells) present in a subject's body fluid, which method uses the compound; an in vitro renal cancer diagnosis method using the compound; a kit containing the compound; the use of the compound for detecting renal cancer-specific enzyme activity; the use of the compound for renal cancer diagnosis; the use of the compound as a renal cancer diagnostic marker. The present invention further relates to a method for treating renal cancer, comprising the steps of performing the above-mentioned method for diagnosing renal cancer. Background Art
[0002] In 2020, more than 430,000 patients worldwide will develop kidney cancer, which is the 14th most commonly diagnosed malignancy worldwide. Kidney cancer is a relatively rare cancer, accounting for 2.4% of newly diagnosed cases of solid tumors worldwide. Malignant kidney tumors are divided into primary and secondary types, the most common of which is renal cell carcinoma (RCC), which accounts for approximately 90% of all malignant kidney tumors. Renal cell carcinoma represents a group of heterogeneous lesions that differ in tissue structure, clinical manifestations and molecular alterations. The most common histological subtype is clear cell renal cell carcinoma (ccRCC), which accounts for 70-80% of all renal cell carcinomas and is also the most aggressive subtype, with the highest local invasion, metastasis and mortality rates. In early kidney cancer, the disease is not accompanied by pain or other characteristic symptoms. More than 30% of patients with renal cell carcinoma have metastases at the time of diagnosis, and in 30% of patients with renal cell carcinoma confined to the organ, metastases will occur after local treatment. Renal cell carcinoma remains a challenge to diagnose and treat. In most patients, the cancer is detected incidentally as a focal lesion during imaging studies (X-ray, CT, MRI) performed intentionally or for other reasons.
[0003] Prognosis depends on the extent of the tumor. Early diagnosis is very important. 75% of patients diagnosed in the early stages survive five years or more.
[0004] There are currently no laboratory tests, no "cancer markers" or set of tests that can reliably diagnose kidney cancer early. Imaging methods such as X-rays, CT scans, MRIs or positron emission tomography (PET) are used to make an effective diagnosis, followed by a tumor biopsy. A small percentage of patients (5-10%) show changes in the expression of specific genes, which make them candidates for genetic testing.
[0005] It is known that the processes of initiation, growth and spread of cancer cells involve many factors, including many enzymes, especially hydrolases and especially proteolytic enzymes. These enzymes catalyze the enzymatic cleavage (hydrolysis or proteolysis) of proteins and peptides into smaller fragments. This process enables cancer cells to expand by colonizing new tissues and promotes the process of blood vessel formation (angiogenesis), which allows nutrients to be effectively delivered to the tumor. In addition, these enzymes also appear due to the death of healthy cells caused by the tumor growth process. All these processes form a characteristic and specific spectrum of enzymatic (proteolytic) activity of cancer cells, which is unique to tumors.
[0006] In the field, it is known that colored peptide molecules can undergo enzymatic decomposition into smaller fragments, resulting in a change or increase in the color of the tested solution. This color development effect is the result of the release of chromophores (e.g., 4-nitroaniline or 2-aminobenzoic acid) from the colored peptide molecules.
[0007] Chromogenic molecules of this type and their uses are known, for example, from Erlanger BF, Kokowsky N, Cohen W., "The preparation and properties of two new chromogenic substrate softrypsin", Arch Biochem Biophys., November 1961; 95: 271-8 and Hojo K, Maeda M, Iguchi S, Smith T, Okamoto H, Kawasaki K. Amino acids and peptides. XXXV. "Facile preparation of p-nitroanilide analogs by the solid-phase method", Chem Pharm Bull (Tokyo), November 2000; 48 (11): 1740-4.
[0008] However, the use of this class of compounds in kidney cancer diagnosis has not been described so far.
[0009] In the prior art, methods for obtaining chromogenic peptides are also known, which involve linking the individual components under appropriate time and stoichiometric conditions. The linking process includes subsequent steps in which the individual elements (amino acid derivatives) are linked, the residues are washed off, the protective groups are successively removed and washed again. This cycle is repeated for each amino acid residue. The peptide obtained is separated from the resin by reaction under acidic conditions. Subsequently, the solution is separated from the resin in a filtration process and the peptide is then precipitated from the solution by a non-polar solvent.
[0010] However, chromogenic peptide compounds suitable for specific early diagnosis of renal cancer or methods for obtaining them are not known in the prior art.
[0011] Therefore, there is an urgent need in the field for a "cancer marker" for renal cancer that can achieve early, sensitive and specific diagnosis of renal cancer in a non-invasive and reliable manner, as well as diagnostic methods and treatment methods using such a diagnostic marker.
[0012] The object of the present invention is to provide a novel and specific renal cancer diagnostic marker and a diagnostic method using such a marker for non-invasive, rapid, sensitive and specific early detection of renal cancer, which method is also suitable for screening tests, as well as a therapeutic method using such a marker.
[0013] These objects are achieved by the invention defined in the attached patent claims, while preferred variants thereof are defined in the dependent claims. Summary of the invention
[0014] The present invention provides a compound having formula 1:
[0015] X1 1 -Leu 2 -Pro 3 -Gly 4 -Thr 5 -X2 6 (Formula 1),
[0016] wherein X1 comprises or consists of the molecule C1, and X2 comprises or consists of the molecule C2,
[0017] The molecules C1 and C2 are a pair of fluorescence donor and fluorescence acceptor.
[0018] The cleavage products of the compound are fragments X1-Leu-Pro-Gly-Thr-OH (fragment 1) and X2 (fragment 2), and enzymatic cleavage occurs when the molecules C1 and C2 are spatially separated to generate a measurable light signal.
[0019] The compounds of the invention are preferably cleaved hydrolytically, more preferably proteolytically.
[0020] Preferably, in the compounds of the present invention, the pair of molecules C1 and C2 is selected from: 2-aminobenzoic acid (ABZ) / 5-amino-2-nitrobenzoic acid (ANB), (ABZ) / pNA, ABZ / ANB-NH2, ABZ / DNP, ABZ / EDDNP, EDANS / DABCYL, TAM / DANSYL, ABZ / Tyr(3-NO2), more preferably the pair of molecules C1 and C2 is (ABZ) / pNA or ABZ / ANB-NH2.
[0021] Preferably, the compound of the present invention is a compound having Formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 (Formula 2) or a compound having Formula 3: ABZ-Leu-Pro-Gly-Thr-pNA (Formula 3).
[0022] More preferably, the compound of the present invention undergoes hydrolytic cleavage to generate the following fragment 1: ABZ-Leu-Pro-Gly-Thr-OH and fragment 2: ANB-NH2.
[0023] The present invention also provides a method for detecting enzyme activity (especially enzyme activity derived from renal cancer cells) present in a subject's body fluid in vitro, the method comprising:
[0024] a) contacting a body fluid sample with a compound having formula 1:
[0025] X1 1 -Leu 2 -Pro 3 -Gly 4 -Thr 5 -X2 6 (Formula 1),
[0026] wherein X1 comprises or consists of the molecule C1, and X2 comprises or consists of the molecule C2,
[0027] The molecules C1 and C2 are a pair of fluorescence donor and fluorescence acceptor.
[0028] and wherein the compound is enzymatically cleaved to generate fragments X1-Leu-Pro-Gly-Thr-OH (fragment 1) and X2 (fragment 2), and
[0029] b) Detection of a measurable light signal generated upon spatial separation of molecules C1 and C2.
[0030] In the method for detecting enzyme activity of the present invention, the enzyme activity is preferably hydrolytic activity, more preferably proteolytic activity.
[0031] In the method for detecting enzyme activity of the present invention, as the compound, it is preferred to use a compound having formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 (Formula 2) or a compound having formula 3: ABZ-Leu-Pro-Gly-Thr-pNA (Formula 3).
[0032] In the method for detecting enzyme activity of the present invention, urine, more preferably human urine, is preferably used as the body fluid.
[0033] The present invention also relates to an in vitro renal cancer diagnosis method, wherein the presence or absence of renal cancer in a subject's body is detected by measuring the renal cancer-specific enzyme activity in a body fluid sample from the subject, wherein the absence of the enzyme activity indicates the absence of renal cancer, and the presence of the enzyme activity indicates the presence of renal cancer.
[0034] In the method for detecting / diagnosing renal cancer of the present invention, the detection of enzyme activity is performed by the method for detecting enzyme activity defined above.
[0035] In the kidney cancer detection / diagnosis method of the present invention, the enzyme activity is measured using a compound having Formula 1:
[0036] X1 1 -Leu 2 -Pro 3 -Gly 4 -Thr 5 -X2 6 (Formula 1),
[0037] wherein X1 comprises or consists of the molecule C1, and X2 comprises or consists of the molecule C2,
[0038] The molecules C1 and C2 are a pair of fluorescence donor and fluorescence acceptor.
[0039] And wherein the compound undergoes enzymatic cleavage to generate fragments X1-Leu-Pro-Gly-Thr-OH (fragment 1) and X2 (fragment 2), and a measurable light signal is generated when molecules C1 and C2 are spatially separated.
[0040] In the renal cancer detection / diagnosis method of the present invention, the body fluid sample is preferably incubated with the compound in a measurement buffer having a neutral or alkaline pH (preferably physiological pH), and the ratio of sample to measurement buffer is in the range of 1:2 to 1:10, preferably 1:5.
[0041] In the method for detecting / diagnosing renal cancer of the present invention, the compound is preferably used at a concentration of 0.1-10 mg / mL, particularly 0.25-7.5 mg / mL.
[0042] In the kidney cancer detection / diagnosis method of the present invention, as the compound, it is preferred to use a compound having formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 (Formula 2) or a compound having formula 3: ABZ-Leu-Pro-Gly-Thr-pNA (Formula 3).
[0043] In the method for detecting / diagnosing renal cancer of the present invention, a urine sample, more preferably human urine, is preferably used as the sample.
[0044] In the kidney cancer detection / diagnosis method of the present invention, the measurement of the enzyme activity preferably includes measuring the absorbance intensity within the range of 300-500nm, more preferably 380-430nm, especially 405nm, within 40-60 minutes, and the temperature within the range of 25-40°C, more preferably 36-38°C.
[0045] The present invention also provides a kit comprising any compound of the present invention and a measurement buffer.
[0046] In the kit of the present invention, the compound is preferably a compound having Formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 or a compound having Formula 3: ABZ-Leu-Pro-Gly-Thr-pNA.
[0047] The present invention also provides use of any of the compounds of the present invention for detecting renal cancer-specific enzyme activity.
[0048] The present invention also provides use of any of the compounds of the present invention for diagnosing renal cancer.
[0049] Preferably, in this use, the diagnosis of renal cancer includes the detection of primary renal cancer, the detection of minimal residual disease after surgical resection of renal cancer and / or the detection of renal cancer recurrence.
[0050] Preferably, the compound in these uses is a compound having Formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 or a compound having Formula 3: ABZ-Leu-Pro-Gly-Thr-pNA.
[0051] The present invention also provides use of any of the compounds of the present invention as a diagnostic marker for renal cancer.
[0052] Preferably, the compound used as a diagnostic marker is a compound having Formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 or a compound having Formula 3: ABZ-Leu-Pro-Gly-Thr-pNA.
[0053] The present invention also provides a method for treating renal cancer, wherein
[0054] a) detecting the renal cancer-specific enzyme activity in a body fluid sample from a subject by any of the methods defined in the present invention, and
[0055] b) treating the subject for kidney cancer if the enzyme activity is found to be present in the sample.
[0056] Preferably, in the therapeutic method of the present invention, after the treatment according to point b) is completed, the renal cancer-specific enzyme activity is monitored at predetermined time intervals.
[0057] Preferably, in the treatment method of the present invention, a urine sample, preferably human urine, is used as a sample.
[0058] Preferably, in the treatment method of the present invention, a compound having formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 or a compound having formula 3: ABZ-Leu-Pro-Gly-Thr-pNA is used as the compound. DETAILED DESCRIPTION
[0059] It should be understood that the present invention is defined by the appended claims. This specification sets forth various non-limiting embodiments and examples of the present invention. The present invention is not limited to any particular method, procedure or reagent for practicing it, unless otherwise specified. The terms and scientific and technical expressions used herein have the meanings commonly known and used by those skilled in the art to which the present invention belongs. However, for the sake of clarity, the following expressions / terms and abbreviations used in the patent should be understood as follows:
[0060] A chromophoric compound or chromophoric molecule is a compound that has chromophoric properties. The chromophoric property refers to the ability of a compound to form a colored product.
[0061] A fluorescent compound or fluorescent molecule refers to a compound that has fluorescent properties. The fluorescent property refers to the ability of a compound to form a product that emits fluorescence.
[0062] NMP represents N-methylpyrrolidone; DMF represents dimethylformamide; DCM represents dichloromethane; pNA represents 4-nitroaniline or p-nitroaniline; ABZ represents 2-aminobenzoic acid, and ANB-NH2 represents the amide of 5-amino-2-nitrobenzoic acid; Boc represents tert-butyloxycarbonyl; Fmoc represents 9-fluorenylmethoxycarbonyl; and TFA represents trifluoroacetic acid.
[0063] In the context of the present invention, the term renal cancer is understood to refer to primary renal cancer (malignant tumor) that develops from tissue located in the kidney. The most common type of renal cancer is renal cell carcinoma (about 90%). Therefore, the term renal cancer used herein includes all malignant renal tumors that develop from tissue located in the kidney.
[0064] In the context of the present invention, the term renal cancer diagnosis is understood to refer to the identification of the disease, particularly in its early stages when other diagnostic methods are not sensitive and / or specific enough. As used herein, renal cancer diagnosis also includes the detection of minimal residual disease (MRD) after surgical resection of renal cancer and the detection of recurrence after completion of renal cancer treatment.
[0065] In the context of the present invention, the term renal cancer treatment is understood to mean a treatment performed at an early stage of disease progression, which allows to significantly prolong the patient's survival time and improve the patient's quality of life.
[0066] In the context of the present invention, the term monitoring is understood to refer to the diagnosis of minimal residual disease (MRD) - ie the presence of a small number of cancer cells surviving in the body (during treatment or remission) in an amount that cannot be detected by standard diagnostic methods.
[0067] In the context of the present invention, the term subject is understood to refer to a human subject or mammal suspected of having renal cancer, or a human subject or mammal belonging to a group at increased risk of renal cancer, or a human subject or mammal after nephrectomy or completion of renal cancer treatment. The subject is preferably a human subject.
[0068] The compounds of the present invention have chromogenic properties due to the presence of chromophores and have fluorescent properties, i.e., they contain fluorescent donor and acceptor molecules. Due to their structure, color increase is observed in the wavelength range of 380-440nm, especially when a body fluid sample from a subject is contacted with renal cancer, while this effect is not observed when reacting with a body fluid sample from a healthy subject or a subject with other types of cancer. These compounds can detect renal cancer-specific enzyme activity in a specific and sensitive manner, especially in the early stages of renal cancer progression. The subject is preferably a human subject. The body fluid is preferably urine, more preferably human urine.
[0069] In the first aspect of the present invention, a novel compound is provided, which has formula 1:
[0070] X1 1 -Leu 2 -Pro 3 -Gly 4 -Thr 5 -X2 6 (Formula 1),
[0071] Wherein X1 is an amino acid derivative or peptide fragment comprising molecule C1, or X1 consists of such molecule C1, X2 is an amino acid derivative or peptide fragment comprising molecule C2, or X2 consists of such molecule C2, wherein molecules C1 and C2 are a pair of fluorescence donors and fluorescence acceptors. The superscript indicates the subsequent position of the residues in the compound and the connection order of the residues during the synthesis process. According to the present invention, in this case, Chemical Formula 1 can also be represented without marking the residue numbers. The core of all compounds of the present invention is a tetrapeptide having the 4 amino acid sequences (Leu-Pro-Gly-Thr) shown, which is also listed as sequence 1 in the sequence table.
[0072] The compounds of the present invention are enzymatically cleaved to generate fragments: X1-Leu-Pro-Gly-Thr-OH (fragment 1) and X2 (fragment 2), and a measurable light signal is generated when the molecules C1 and C2 are spatially separated. The measurable light signal is measured by measuring the absorbance / fluorescence change after enzymatic cleavage of the compound. Preferably, the molecules C1 and C2 are separated from each other by no more than 10 amino acid residues, which ensures effective quenching of the fluorescent donor by the fluorescent acceptor. It is obvious to those skilled in the art that the critical factor is the distance between the fluorescent donor and the acceptor. Therefore, when the amino acid sequence separating the molecules C1 and C2 is folded into a twisted or compressed secondary structure, resulting in the molecules C1 and C2 being closer relative to the primary structure, the distance between the molecules C1 and C2 can be greater than 10 amino acid residues.
[0073] Due to the chromogenic properties of the compound and the presence of a reaction site at position 5 that enables enzymatic (preferably proteolytic) cleavage into smaller fragments, it is particularly suitable for use as a diagnostic marker, especially a specific diagnostic biomarker for renal cancer, and is particularly suitable for early diagnosis of renal cancer.
[0074] In preferred embodiments, the compounds of the invention are cleaved hydrolytically, more preferably proteolytically.
[0075] In a preferred embodiment, the pair of molecules C1 and C2 is selected from the following group: 2-aminobenzoic acid (ABZ) / 5-amino-2-nitrobenzoic acid (ANB), (ABZ) / pNA, ABZ / ANB-NH2, ABZ / DNP, ABZ / EDDNP, EDANS / DABCYL, TAM / DANSYL, ABZ / Tyr(3-NO2), more preferably the pair of molecules C1 and C2 is (ABZ) / pNA or ABZ / ANB-NH2. In a preferred embodiment, the compound of the present invention is:
[0076] A compound having formula 2:
[0077] ABZ 1 -Leu 2 -Pro 3 -Gly 4 -Thr 5 -ANB 6 -NH2 (Formula 2) or
[0078] A compound having formula 3:
[0079] ABZ 1 -Leu 2 -Pro 3 -Gly 4 -Thr 5 -pNA6 (Formula 3),
[0080] Wherein ABZ represents 2-aminobenzoic acid, ANB-NH2 represents the amide of 5-amino-2-nitrobenzoic acid, and pNA represents 4-nitroaniline.
[0081] The compound undergoes hydrolytic cleavage to generate the following fragment 1: ABZ-Leu-Pro-Gly-Thr-OH and fragment 2: ANB-NH2 for the compound of formula 2, and the following fragment 1: ABZ-Leu-Pro-Gly-Thr-OH and fragment 2: pNA for the compound of formula 3. Therefore, fragment 2 is a free chromophore.
[0082] The spatial separation of molecules C1 and C2 is the result of enzymatic cleavage of the compound of the present invention, which will generate a measurable light signal because the fluorescence emitted from the fluorescence donor is no longer quenched by the fluorescence acceptor. This measurable light signal can be preferably detected in the wavelength range of 300-500nm, more preferably detected in 380-430nm.
[0083] The compounds of the present invention can be obtained by known methods. For example, they can be obtained by carrying out a method for obtaining chromogenic peptides on a solid support in the form of a resin with an Fmoc group, which is removed during the reaction. For example, it can be an amide resin, such as Teenage S RAM or RinkAmide, but any other commercially available resin can also be used. The resin used to carry out this process should be properly prepared. The preparation of the resin includes increasing its volume by repeatedly washing with a hydrophobic solvent. Preferably, a resin with a deposition amount of 0.23 mmol / g is used. The Fmoc protecting group must be removed from the resin by washing with a 20% solvent solution.
[0084] The known process for obtaining chromogenic peptides then consists in linking the individual components under appropriate time and stoichiometric conditions. The linking process includes subsequent steps in which the individual elements (amino acid derivatives) are linked, the residues are washed off, the protective groups are successively removed and washed again. This cycle is repeated for each amino acid residue. The peptide obtained is separated from the resin by reaction under acidic conditions. The solution is then separated from the resin in a filtration process and the peptide is then precipitated from the solution by a non-polar solvent. The peptide precipitate is obtained by centrifugation.
[0085] An exemplary, detailed but non-limiting method for synthesizing compounds of the present invention is described below and in detail in Example 1.
[0086] The synthesis method of the compounds of the present invention is carried out on a solid support, which preferably has an Fmoc group, wherein before the process starts, the solid support is increased in size by repeated washing with a hydrophobic solvent, preferably with dimethylformamide, dichloromethane or N-methylpyrrolidone, and the Fmoc protecting group is removed, preferably with a 10-30% piperidine solution in a solvent such as dimethylformamide, dichloromethane or N-methylpyrrolidone.
[0087] The method then proceeds as follows:
[0088] a) before depositing 5-amino-2-nitrobenzoic acid, ANB (or another chromophore suitable for use according to the invention, as defined in the claims) on the resin, the solid support is washed with a 3-6% solution of N-methylmorpholine (NMM) in DMF and then with DMF, after which a solution of ANB in DMF is prepared to which TBTU, DMAP and finally diisopropylethylamine (DIPEA) are added in order, in excess relative to the polymer deposited: ANB / TBTU / DMAP / DIPEA, 3:3:2:6 ; the mixture thus prepared is added to the resin and stirred until homogeneous, after which the resin is filtered under reduced pressure and washed with DMF, DCM and isopropanol, and then ANB is connected to the resin by continuing with hexafluorophosphate-O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium (HATU) and then hexafluorophosphate-O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium (HATU), in excess, and upon completion, the solid support is washed successively with DMF, DCM and isopropanol and gently dried;
[0089] b) by reacting with an amino acid derivative -Fmoc-Thr(OtBu)-OH, wherein at least a five-fold molar excess of the amino acid derivative relative to the amount deposited on the resin is dissolved in anhydrous pyridine and contacted with the resin deposited with ANB, after which the whole mixture is cooled to not less than -20°C, then POCl3 is added in a 1:1 ratio with the amount of the amino acid derivative used, and then the whole mixture is stirred, then stirred at room temperature and stirred at an elevated temperature, and when the reaction is complete, the resin is filtered under reduced pressure, washed with DMF and MeOH and gently dried, after which the intermediate compound obtained is subjected to an acylation process, Leu-Pro-Gly fragments are sequentially connected, and the amino acid residues are connected to ANB;
[0090] c) acylation is carried out from residue 6 to 1 by using an amino acid derivative, preferably Fmoc-Gly-OH, followed by Fmoc-Pro-OH, then Fmoc-Leu-OH and finally Boc-Abz-OH in the last step of the synthesis, using diisopropylcarbodiimide as coupling agent, used in excess, and after completion of each step, the intermediate compounds obtained are acylated with DMF and preferably with a chloroaniline test (a test for the presence of free amino groups), in which the attachment of the amino acid derivative is monitored;
[0091] d) removing the Fmoc protecting group by washing with 10-30% piperidine solution in DMF, followed by washing once each with DMF, isopropanol and dichloromethane;
[0092] e) separating the peptide from the resin by using a mixture of: TFA:phenol:water:TIPS, maintaining a ratio of 88:5:5:2 (v / v / v / v), stirring for at least one hour, preferably three hours, and filtering the resulting precipitate under reduced pressure, followed by washing with diethyl ether, and centrifuging the resulting peptide;
[0093] f) The peptide is dissolved in water with the aid of ultrasound and then freeze-dried to prepare the finished product.
[0094] A second aspect of the present invention provides a method for in vitro detection of enzyme activity (preferably proteolytic activity) present in a subject's body fluid, in particular a method for detecting enzyme activity derived from renal cancer cells, the method comprising: a) contacting a body fluid sample with a compound of the present invention; b) detecting a measurable optical signal generated when the molecules C1 and C2 present in the compound of the present invention are spatially separated. In a preferred embodiment of this aspect, the subject examined in this case is a human subject. In another preferred embodiment of this aspect, the body fluid is urine, in particular human urine.
[0095] In a preferred embodiment of this aspect, a compound having formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 or a compound having formula 3: ABZ-Leu-Pro-Gly-Thr-pNA is used.
[0096] The third aspect of the present invention provides a method for in vitro diagnosis of renal cancer, wherein the presence of renal cancer in a subject is detected by measuring renal cancer-specific enzyme activity in a body fluid sample from the examined subject, wherein the absence of the enzyme activity indicates the absence of renal cancer, and the presence of the enzyme activity indicates the presence of renal cancer. The detection of this enzyme activity is preferably carried out using a method for detecting enzyme activity as discussed above. In a preferred embodiment of this aspect, the subject is a human subject. In a preferred embodiment of this aspect, the body fluid is urine, in particular human urine. In a preferred embodiment of this aspect, the renal cancer-specific enzyme activity is proteolytic activity. In a preferred embodiment of this aspect, a compound having formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 or a compound having formula 3: ABZ-Leu-Pro-Gly-Thr-pNA is used.
[0097] Furthermore, in a preferred embodiment of this aspect, the measurement of the enzyme activity in the method of the present invention comprises measuring the absorbance intensity within the range of 300-500 nm, preferably 380-430 nm, in particular 405 nm, within 40-60 minutes, at a temperature within the range of 25-40° C., preferably 36-38° C. This enables the measurable optical signal of the maximum intensity generated by the increase in absorbance or fluorescence to be obtained.
[0098] In addition, in a preferred embodiment of the method of the present invention, the measurement of the enzyme activity is performed using a compound of the present invention in a concentration range of 0.1-10 mg / mL, more preferably a concentration of 1 mg / mL. In a preferred embodiment of the method of the present invention, the test sample is incubated with a body fluid sample (preferably human urine) in a measurement buffer having a neutral or alkaline pH (preferably physiological pH), and the ratio of the sample (e.g., urine sample) to the measurement buffer is 1:2 to 1:10, preferably 1:5. The sample is preferably collected from a subject referred for a diagnosis of renal cancer. Preferably, the absorbance intensity is measured within a range of 300-500nm, preferably 380-430nm, especially 405nm, within 40-60 minutes, at a temperature range of 25-40°C, preferably 36-38°C. Under the above conditions, a measurable optical signal of maximum intensity due to an increase in absorbance or fluorescence is obtained.
[0099] In a fourth aspect, the present invention provides a kit comprising any compound of the present invention and a measurement buffer. The measurement buffer is known in the art and is suitable for use in the kit of the present invention, for example, but not limited to, Tris-HCl buffer. In a preferred embodiment, in the kit of the present invention, the compound is a compound having Formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 or a compound having Formula 3: ABZ-Leu-Pro-Gly-Thr-pNA.
[0100] In a fifth aspect, the present invention provides the use of the compounds of the present invention in detecting renal cancer-specific enzyme activity. In a sixth aspect, the present invention provides the use of the compounds of the present invention in the diagnosis of renal cancer. Preferably, according to the present invention, the diagnosis of renal cancer includes the detection of primary renal cancer, the detection of minimal residual disease after surgical resection of renal cancer, and / or the detection of renal cancer recurrence after previously completed renal cancer treatment.
[0101] In a seventh aspect, the present invention provides a compound of the present invention for use as a diagnostic marker for the detection of renal cancer. In a preferred embodiment of this aspect, the compound is a compound having Formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 or a compound having Formula 3: ABZ-Leu-Pro-Gly-Thr-pNA.
[0102] In an eighth aspect, the present invention provides a method for treating renal cancer, wherein:
[0103] a) detecting the presence of renal cancer-specific enzyme activity in a body fluid sample from a subject to be examined by any of the methods of the invention as defined above;
[0104] b) treating the subject for kidney cancer when the enzyme activity is found in the sample.
[0105] In a preferred embodiment of the method of treatment, after completion of the treatment according to point b), the renal cancer-specific enzyme activity is monitored at predetermined time intervals, such as weekly, weekly, weekly, monthly, monthly, annually, or any other interval deemed appropriate by the skilled person, as known in the art, in order to detect minimal residual disease or recurrence after surgical resection of renal cancer. In addition, in a preferred embodiment of the method, a urine sample, preferably human urine, is used as a test sample. In a preferred embodiment of the method of treatment, a compound having formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 (Formula 2) or having formula 3: ABZ-Leu-Pro-Gly-Thr-pNA (Formula 3) is used as the compound.
[0106] The present invention has the advantage of providing a novel compound having properties that make it suitable for specific and sensitive detection of renal cancer specific enzyme activity, for use as a diagnostic biomarker for renal cancer detection, for rapid, non-invasive diagnosis of renal cancer while being able to detect renal cancer in the early stages of renal cancer progression. Another advantage is that the diagnostic method of the present invention can be successfully used for screening tests. This enables comprehensive diagnosis at the early stages of cancer progression, thereby allowing for more effective treatment. Early diagnosis enables surgical treatment, which significantly prolongs the patient's survival time. It is also important in monitoring the effectiveness of surgical treatment and / or chemotherapy for renal cancer because minimal residual disease or recurrence, if present, can be detected.
[0107] The invention will now be illustrated in the following figures and the following examples, which however are not intended in any way to limit the scope of the invention as defined in the claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0108] Figure 1 Shown are the results of chromatographic analysis of the cleavage of the substrate (i.e., ABZ-Leu-Pro-Gly-Thr-ANB-NH2) in urine samples from patients with renal cancer.
[0109] Figure 2 Shown are the hydrolysis rates of the substrate (ABZ-Leu-Pro-Gly-Thr-ANB-NH2) in urine samples from subjects diagnosed with renal cancer (samples N1-N20) and urine from healthy subjects (samples 21-40). Arabic numerals indicate the number of the selected urine sample.
[0110] Figure 3 The substrate ABZ is shown 1 -Leu 2 -Pro 3 -Gly 4 -Thr 5 -ANB 6 -NH2 (i.e., compound of formula 2) in urine samples of subjects diagnosed with renal cancer (sample 1) and urine samples from subjects diagnosed with other tumor diseases (samples 2-9) in hydrolysis selectivity. Arabic numerals indicate the number of a given cancer type. Samples for each cancer test were from 20 different patients for each tested cancer. The results are averages for a given cancer type. The results show the selectivity of substrate cleavage in urine of patients with renal cancer compared to urine samples from patients with other tumors.
[0111] Figure 4 The substrate ABZ is shown 1 -Leu 2 -Pro 3 -Gly 4 -Thr5 -ANB 6 Dependence of the hydrolysis level of -NH2 on pH conditions.
[0112] Example
[0113] The present invention is illustrated by the following non-limiting examples. Unless otherwise stated, the following examples use known and / or commercially available equipment, methods, reaction conditions, reactants and reagent sets, which are conventional in the art to which the present invention belongs and are recommended by the manufacturers of the corresponding reactants and kits.
[0114] Example 1: Synthesis of the compounds of the present invention
[0115] This embodiment describes the synthesis of a representative compound of the present invention, namely compound ABZ 1 -Leu 2 -Pro 3 -Gly 4 -Thr 5 -ANB 6 -NH2. The remaining peptides of the present invention can be synthesized in a similar manner. The superscripts indicate the subsequent position of the residues in the compound and the order in which the residues are connected during the synthesis. The compounds of the present invention can also be represented by similar formulas without marking the residue positions, which does not change the order of the residues in the compound because it remains unchanged.
[0116] 1. Obtaining chromogenic peptides
[0117] The first step in the synthesis is to obtain the chromogenic peptide, which is obtained by solid phase synthesis on a solid support using Fmoc / tBu chemistry (ie using protecting groups).
[0118] The following amino acid derivatives were synthesized using solid phase chemical synthesis:
[0119] Boc-ABZ, Fmoc-Leu, Fmoc-Pro, Fmoc-Gly, Fmoc-Thr(OtBu),
[0120] The sequence ABZ was obtained 1 -Leu 2 -Pro 3 -Gly 4 -Thr 5 -ANB 6 -NH2 compound, wherein ABZ is 2-aminobenzoic acid, ANB-NH2 is the amide of 5-amino-2-nitrobenzoic acid, and ANB is 5-amino-2-nitrobenzoic acid.
[0121] The synthesis of the compound of the present invention, a diagnostic marker for the detection of renal cancer, was carried out on a solid support capable of converting 5-amino-2-nitrobenzoic acid to ANB-NH2 amide, namely the amide resin TentaGel S RAM from RAPP Polymere (Germany) with a deposition amount of 0.23 mmol / g. However, any other amide resin may be used, such as RinkAmide (Germany).
[0122] The synthesis of this compound was performed manually using a laboratory shaker. In most steps, a 25 mL fritted syringe was used as the reactor for solid phase synthesis.
[0123] All the final compounds obtained contain 2-aminobenzoic acid (ABZ) at position 1 (i.e. N-terminus) of their sequence and a 5-amino-2-nitrobenzoic acid (ANB) molecule at position 6 (i.e. C-terminus). ABZ acts as a fluorescence donor here, while ANB acts as a fluorescence quencher and is also a chromophore. These peptides have at least and preferably one reactive site in their sequence located between the amino acid residues Thr-ANB-NH2 (i.e. position 5 of the compound). The synthesis process is to connect the amino acid derivatives from residues 6 to 1 (i.e. from C-terminus to N-terminus).
[0124] b) Deposition of ANB on TentaGel S RAM resin
[0125] The peptide synthesis was carried out on TentaGel S RAM resin from Rapp Polymere, which was deposited at 0.23 mmol / g. In a first step, the resin was prepared, including loosening it by washing cycles. Subsequently, the Fmoc amino protecting group was removed from the solid support with a 20% solution of piperidine in NMP. Solvent washing cycles were then performed. To confirm the presence of free amino groups, a chloroaniline test was performed.
[0126] Solvent Wash Cycle:
[0127] DMF 1×10 min; IsOH 1×10 min; DCM 1×10 min.
[0128] Removal of Fmoc protection:
[0129] DMF 1 x 5 min; 20% piperidine in NMP 1 x 3 min; 20% piperidine in NMP 1 x 8 min.
[0130] Solvent Wash Cycle:
[0131] DMF 3×2 min; IsOH 3×2 min; DCM 3×2 min.
[0132] c) Chloroaniline test
[0133] The chloroaniline test was performed by transferring a few pellets of resin from the reactor (syringe) into a glass ampoule with a spatula, to which 100 μL of a saturated solution of p-chloroaniline in toluene and 50 μL of fresh acetaldehyde were added. After 10 minutes, the pellets were checked for color.
[0134] At that stage, the green color of the particles was obtained after testing, which confirmed the presence of free amino groups. After confirming the removal of the 9-Fluorenylmethoxycarbonyl protecting group from the resin, the next step can be carried out, which is the attachment of the ANB derivative (5-amino-2-nitrobenzoic acid).
[0135] d) Deposition of 5-amino-2-nitrobenzoic acid on a solid support
[0136] The first step in the synthesis of a peptide library (peptide mixture) is the deposition of ANB on 1 g of resin. Prior to the attachment of the chromophore, the resin used for the reaction is washed with the following solvents: DMF, DCM and then DMF again, after which the Fmoc-protection is removed from the functional groups of the solid support. A cycle of removing the Fmoc-protection comprises the following steps:
[0137] Removal of Fmoc-protection:
[0138] 20% piperidine in NMP 1 x 3 min; 20% piperidine in NMP 1 x 8 min.
[0139] e) Washing
[0140] DMF 3×2 min; IsOH 3×2 min; DCM 3×2 min.
[0141] f) Chloroaniline test
[0142] The resin with free amino groups is washed with 5% N-methylmorpholine (NMM) in DMF and then with DMF. The removal of Fmoc-protection and washing cycles are carried out in a Merrifield vessel. In a separate flask, ANB is dissolved in DMF, followed by the addition of TBTU, DMAP and finally diisopropylethylamine (DIPEA) in an excess ratio relative to polymer deposition of: ANB / TBTU / DMAP / DIPEA, 3:3:2:6 (volume ratio). The mixture prepared in this way is added to the resin and stirred for 3 hours. The resin is filtered under reduced pressure, washed with DMF, DCM and isopropanol, and the entire acylation process is repeated twice. For the subsequent reaction of attaching ANB to the resin, O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) was used, followed by O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU). In the last step, the resin was washed with DMF, DCM, and isopropanol in sequence and dried in air.
[0143] g) Attach the C-terminal amino acid residue (Fmoc-Thr(OtBu)-OH) to ANB
[0144] The corresponding amino acid derivative (9-fold molar excess relative to the amount deposited on the resin) was dissolved in pyridine and transferred to the flask containing the resin deposited with ANB. The entire mixture was cooled to -15°C (by ice bath: 1 part by weight of NH4Cl, 1 part by weight of NaNO3, 1 part by weight of ice). After reaching the desired temperature, POCl3 (in a 1:1 ratio with the amount of amino acid derivative used) was added and stirred on a magnetic stirrer: 20 minutes at -15°C, 30 minutes at room temperature and 6 hours at 40°C (oil bath). When the reaction was complete, the resin was filtered under reduced pressure, washed with DMF and MeOH and dried.
[0145] Next, the residue was attached at the P2 position (Fmoc-Gly).
[0146] Before each amino acid residue connection, the resin was washed with DMF for 5 minutes. Diisopropylcarbodiimide was used as a coupling agent in subsequent connections. This process was repeated twice.
[0147] After each acylation, a resin wash cycle was initiated followed by a chloroaniline test to monitor the attachment of the amino acid derivative to the free amino groups of the resin.
[0148] Solvent Wash Cycle:
[0149] DMF 3×2 min; IsOH 3×2 min; DCM 3×2 min
[0150] Chloroaniline test:
[0151] Since the color of the particles was first green and then gray after the initial two coupling steps, it was necessary to perform another acylation, which resulted in colorless resin particles when tested with chloranil. This confirmed that the ANB was attached to the TentaGel SRAM resin and could therefore proceed to the next step of peptide synthesis.
[0152] h) Attachment of subsequent protected amino acid residues
[0153] The resin (in the reactor) with the linker fragment ANB-Thr(OtBu) was washed with DMF, and then the Fmoc protection of the amino group was removed to allow the connection of the protected amino acid derivative Gly.
[0154] Removal of Fmoc protection:
[0155] DMF 1 x 5 min; 20% piperidine in NMP 1 x 3 min; 20% piperidine in NMP 1 x 8 min.
[0156] Solvent Wash Cycle:
[0157] DMF 3×2 min; IsOH 3×2 min; DCM 3×2 min.
[0158] Chloroaniline test:
[0159] The chloroaniline test yielded a positive result, as evidenced by the green color of the resin particles. Therefore, the next step - attachment of the amino acid residue Fmoc-Pro-OH - could be carried out.
[0160] Connecting amino acid derivatives
[0161] Prior to the coupling process, the resin was washed with DMF. When coupling protected serine residues, the composition of the coupling mixture remained unchanged.
[0162] After each acylation, a solvent wash cycle was performed according to the prescribed procedure, followed by a chloroaniline test for the presence of free amino groups in the solution.
[0163] Solvent Wash Cycle:
[0164] DMF 3×2 min; IsOH 3×2 min; DCM 3×2 min.
[0165] Chloroaniline test:
[0166] In the test after the second acylation, the resin particles were colorless and thus could be used for the next step of the synthesis, which was the introduction of another protected amino acid derivative, Fmoc-Leu, and 2-aminobenzoic acid molecules. The coupling process was carried out according to the procedures discussed previously.
[0167] The test after attachment of the above residues showed positive results - the resin particles were colorless.
[0168] 2. Removal of peptides from solid support
[0169] After synthesis, the amide of the ABZ-Leu-Pro-Gly-Thr-ANB-NH2 peptide was removed from the solid support using a mixture of TFA:phenol:water:TIPS (88:5:5:2, volume ratio) on a magnetic stirrer in a round-bottom flask, while removing the side chain protecting groups.
[0170] After 3 hours, the contents in the flask were filtered under reduced pressure in a Schott funnel and washed with diethyl ether. The resulting precipitate was centrifuged for 20 minutes on a SIGMA2K30 centrifuge (laboratory centrifuge). The precipitate obtained after centrifugation was dissolved in water by ultrasound and then freeze-dried. The remaining compounds of the present invention can be obtained by a similar method.
[0171] The identity / characteristics of the novel compounds of the present invention were confirmed using HPLC analysis. The conditions for HPLC analysis were as follows: RPBio Wide Pore Supelco C8 column, 250 mm×4 mm, phase system A was 0.1% TFA in water, B was 80% acetonitrile in A, flow rate was 1 mL / min, and UV detection wavelength was 226 nm.
[0172] The analysis results confirmed that the compound of the present invention was obtained.
[0173] Example 2. Testing the properties of the peptides of the present invention as cancer markers
[0174] The activity of the novel compounds of the present invention was studied in a group of 20 subjects diagnosed with renal cancer using representative compounds of the present invention. The mechanism of action of the compounds of the present invention (including representative compounds of formula 2) is a specific enzymatic cleavage, more specifically enzymatic hydrolysis at a specific position, which leads to the release of free molecules of the corresponding chromophore: ANB-NH2 (amide of 5-amino-2-nitrobenzoic acid) in the compounds of formula 2 and pNA (p-nitroaniline) in the compounds of formula 3, which have absorbance in the wavelength range of 320-480nm, particularly at 380-430nm, especially 405nm. The remaining compounds of the present invention have a similar mechanism of action.
[0175] For this purpose, the representative compound ABZ of the present invention1 -Leu 2 -Pro 3 -Gly 4 -Thr 5 -ANB 6 -NH2 was dissolved in dimethyl sulfoxide (concentration of 0.5 mg / mL), and then 50 μL of this solution was mixed with 120 μL of buffer (200 mM Tris-HCl, pH 8.0) and 80 μL of urine from a subject with renal cancer. The measurement was performed on a 96-well plate for measuring absorbance, and each sample was analyzed three times at 37°C. The measurement time was 60 minutes. During the measurement, the characteristic wavelength of the chromophore (ANB-NH2) being released was monitored at 405 nm (range 380-430 nm).
[0176] like Figure 1 As shown, RP HPLC analysis of a randomly selected system of urine samples collected from a person diagnosed with renal cancer showed that the compound of the present invention was cleaved into the peptide fragment ABZ-Leu-Pro-Gly-Thr-OH and the chromophore group (ANB-NH2) of the compound.
[0177] The measurements showed that the color intensity of the solution increased over time in all urine samples collected from people diagnosed with kidney cancer. The magnitude of the observed increase in absorbance over time varied for each sample examined. A different effect was obtained for samples from 20 healthy subjects (samples 21-40), as no increase in absorbance within the diagnostic range was observed in any of the 20 urine samples tested.
[0178] The tests performed showed that cleavage occurred in all samples N1-N20 from people with kidney cancer, but in samples N3 and N6, the substrate (i.e., ABZ-Leu-Pro-Gly-Thr-ANB-NH2) was cleaved less efficiently than in samples N5 or N20 ( Figure 2 , Table 1). This result may be due to differences in the activity and quantity of the enzymes responsible for enzymatic cleavage (proteolysis). In addition, the results in Table 1 show that incubation of the substrate solution (compounds of the present invention) with urine samples from healthy subjects (without cancer diagnosis, labeled with Arabic numerals from 21 to 40 in sequence) does not result in an increase in absorbance, so no hydrolysis of the tested compounds occurs. The results indicate that there is no proteolytic enzyme specific / characteristic to renal cancer.
[0179] Table 1. Absorbance analysis results
[0180]
[0181]
[0182] Furthermore, the dependence of the cleavage selectivity of the substrate (i.e., the compound of the present invention) on the type of cancer examined was studied. Figure 3 As shown in Table 2, the test substrate ABZ 1 -Leu 2 -Pro 3 -Gly 4 -Thr 5 -ANB 6 -NH2, when incubated with samples collected from patients with the following cancers: testicular cancer, prostate cancer, pancreatic cancer, bile duct cancer, lung cancer, ovarian cancer, rectal cancer, did not undergo cleavage and did not cause an increase in absorbance within the specified range. The samples tested were in each case a mixture of 20 samples from each cancer studied. This shows that the compounds of the invention have cleavage selectivity, making them suitable for specific detection of renal cancer-specific enzyme activity and specific diagnosis of renal cancer.
[0183] Table 2. Results of cleavage selectivity analysis
[0184] Kidney cancer 1 0,01416 0,01476 0,01874 Stomach 2 0 0 0 Lung 3 0 0 0 Intestine 4 0 0 0 Prostate 5 0 0 0 Bladder 6 0 0 0 Pancreas 7 0 0 0 Ovaries 8 0 0 0 Liver 9 0 0 0
[0185] In addition, the dependence of the proteolytic activity of representative compounds of the present invention on the reaction pH was measured. The experiments showed that at least one enzyme of the studied materials exhibited maximum activity at alkaline pH ( Figure 4 ).
[0186] The analysis performed confirmed that the compounds of the present invention are suitable for sensitive and specific detection of renal cancer-specific enzyme activities, and are also suitable for specific diagnosis of renal cancer and as diagnostic markers for renal cancer. The mechanism of action of the compounds of the present invention lies in their specific enzymatic cleavage at specific locations, which leads to the release of free chromophore molecules, thereby generating a measurable light signal that can be used for diagnostic purposes, in particular in the diagnosis of renal cancer of the present invention.
[0187]
[0188]
[0189]
Claims
1. A compound having formula 1: X1 1 -Leu 2 -Pro 3 -Gly 4 -Thr 5 -X2 6 (Formula 1), wherein X1 comprises or consists of the molecule C1, and X2 comprises or consists of the molecule C2, The molecules C1 and C2 are a pair of fluorescence donor and fluorescence acceptor. And wherein the compound undergoes enzymatic cleavage to generate fragments X1-Leu-Pro-Gly-Thr-OH (fragment 1) and X2 (fragment 2), generating a measurable light signal when molecules C1 and C2 are spatially separated.
2. The compound according to claim 1, which is hydrolytically cleaved, preferably proteolytically cleaved.
3. The compound according to claim 1 or 2, wherein the pair of molecules C1 and C2 is selected from: 2-aminobenzoic acid (ABZ) / 5-amino-2-nitrobenzoic acid (ANB), (ABZ) / pNA, ABZ / ANB-NH2, ABZ / DNP, ABZ / EDDNP, EDANS / DABCYL, TAM / DANSYL, ABZ / Tyr(3-NO2), preferably the pair of molecules C1 and C2 is ABZ / pNA or ABZ / ANB-NH2.
4. The compound according to any one of claims 1 to 3, which is a compound having Formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 (Formula 2) or a compound having Formula 3: ABZ-Leu-Pro-Gly-Thr-pNA (Formula 3).
5. The compound according to claim 4, which undergoes hydrolytic cleavage to generate the following fragment 1: ABZ-Leu-Pro-Gly-Thr-OH and fragment 2: ANB-NH2.
6. A method for detecting in vitro enzyme activity present in a subject's body fluid, in particular enzyme activity derived from renal cancer cells, comprising: a) contacting a body fluid sample with a compound having formula 1: X1 1 -Leu 2 -Pro 3 -Gly 4 -Thr 5 -X2 6 (Formula 1), wherein X1 comprises or consists of the molecule C1, and X2 comprises or consists of the molecule C2, The molecules C1 and C2 are a pair of fluorescence donor and fluorescence acceptor. and wherein the compound is enzymatically cleaved to generate fragments X1-Leu-Pro-Gly-Thr-OH (fragment 1) and X2 (fragment 2), and b) Detection of a measurable light signal generated upon spatial separation of molecules C1 and C2.
7. The in vitro method according to claim 6, wherein the enzymatic activity is a hydrolytic activity, preferably a proteolytic activity.
8. The in vitro method according to claim 6 or 7, wherein As the compound, a compound having Formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 (Formula 2) or a compound having Formula 3: ABZ-Leu-Pro-Gly-Thr-pNA (Formula 3) was used.
9. The method according to any one of claims 6 to 8, wherein urine, preferably human urine, is used as the body fluid.
10. An in vitro method for diagnosing renal cancer, wherein the presence or absence of renal cancer in a subject is detected by measuring the activity of a renal cancer-specific enzyme in a body fluid sample from the subject, wherein the absence of the enzyme activity indicates the absence of renal cancer, and the presence of the enzyme activity indicates the presence of renal cancer.
11. The method according to claim 10, wherein the detection of the enzyme activity is performed by a method as defined in any one of claims 6 to 9.
12. The method according to claim 10 or 11, wherein the measurement of the enzyme activity is carried out using a compound having formula 1: X1 1 -Leu-Pro-Gly-Thr-X2 6 (Formula 1), wherein X1 comprises or consists of the molecule C1, and X2 comprises or consists of the molecule C2, The molecules C1 and C2 are a pair of fluorescence donor and fluorescence acceptor. And wherein the compound undergoes enzymatic cleavage to generate fragments X1-Leu-Pro-Gly-Thr-OH (fragment 1) and X2 (fragment 2), and a measurable light signal is generated when molecules C1 and C2 are spatially separated.
13. The method according to any one of claims 10 to 12, wherein the body fluid sample is incubated with the compound in a measurement buffer having a neutral or alkaline pH, preferably a physiological pH, the ratio of sample to measurement buffer being in the range of 1:2 to 1:10, preferably 1:
5.
14. The method according to any one of claims 10 to 13, wherein the compound is used in a concentration of 0.1-10 mg / mL, in particular in a concentration of 0.25-7.5 mg / mL.
15. The method according to any one of claims 10 to 14, wherein a compound having Formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 (Formula 2) or a compound having Formula 3: ABZ-Leu-Pro-Gly-Thr-pNA (Formula 3) is used as the compound.
16. The method according to any one of claims 10 to 15, wherein a urine sample, preferably human urine, is used as the sample.
17. The method according to any one of claims 10 to 16, wherein the measurement of the enzyme activity comprises measuring the absorbance intensity in the range of 300-500 nm, preferably 380-430 nm, in particular 405 nm, between 40-60 minutes, at a temperature in the range of 25-40°C, preferably 36-38°C.
18. A kit comprising a compound as defined in any one of claims 1 to 5 and a measurement buffer.
19. The kit according to claim 18, wherein the compound is a compound having Formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 (Formula 2) or a compound having Formula 3: ABZ-Leu-Pro-Gly-Thr-pNA (Formula 3).
20. Use of a compound as defined in any one of claims 1 to 5 for detecting renal cancer-specific enzyme activity.
21. Use of a compound as defined in any one of claims 1 to 5 for the diagnosis of renal cancer.
22. The use according to claim 21, wherein the diagnosis of renal cancer comprises the detection of primary renal cancer, the detection of minimal residual disease after surgical resection of renal cancer and / or the detection of renal cancer recurrence.
23. The use according to any one of claims 21 to 22, wherein the compound is a compound having Formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 (Formula 2) or a compound having Formula 3: ABZ-Leu-Pro-Gly-Thr-pNA (Formula 3).
24. A compound as defined in any one of claims 1 to 5 for use as a diagnostic marker for renal cancer.
25. The compound for use according to claim 24, wherein the compound is a compound having Formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 (Formula 2) or a compound having Formula 3: ABZ-Leu-Pro-Gly-Thr-pNA (Formula 3).
26. A method for treating kidney cancer, wherein a) detecting the renal cancer-specific enzyme activity in a body fluid sample from a test subject by the method defined in any one of claims 6 to 9, and b) treating the subject for kidney cancer if the enzyme activity is found to be present in the sample.
27. The method of claim 26, wherein after completion of the treatment according to point b), the renal cancer-specific enzyme activity is monitored at predetermined time intervals.
28. The method according to claim 26 or 27, characterized in that A urine sample, preferably human urine, is used as the sample.
29. The method according to any one of claims 26 to 28, wherein a compound having Formula 2: ABZ-Leu-Pro-Gly-Thr-ANB-NH2 (Formula 2) or a compound having Formula 3: ABZ-Leu-Pro-Gly-Thr-pNA (Formula 3) is used as the compound.
